TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02014870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1:1000 Live wild-type A/California/H1N1 2009
Description: 1:1000 dilution of neat virus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1:100 Live wild-type A/California/H1N1 2009
Description: 1:100 dilution of neat virus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1:10 Live wild-type A/California/H1N1 2009
Description: 1:10 dilution of neat virus
Study: NCT01622283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Levocetirizine
Study: NCT04700267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 film-coated tablet
Description: GLPG3970 for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo film-coated tablet
Description: Placebo for oral administration
Study: NCT03095092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 400 mg
Description: 4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 400 mg
Description: 4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
Study: NCT01475955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broad Area ALA 1-hour incubation
Description: 20% ALA, broad area, 1 hour incubation
Study: NCT01622283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: Cetirizine
Study: NCT02735499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinum toxin A
Description: Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
Study: NCT03970408

Intervention type: PROCEDURE
Intervention: MNT1
Description: Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping.

Intervention type: PROCEDURE
Intervention: MNT1
Description: Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping.
Study: NCT00510965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injection ranibizumab
Description: Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
Study: NCT04572360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory Exercise
Description: Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory Exercise
Description: Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training
Study: NCT01420744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT086
Description: BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.~Infusion rate:~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period.
Study: NCT04572360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Bai He Gu Jin Tang
Description: The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Bai He Gu Jin Tang
Description: The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.
Study: NCT01753050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke volume monitoring
Description: Pulse contour stroke volume monitoring
Study: NCT03812627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections
Description: All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections
Description: All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections
Description: All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections
Description: All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autopsy
Description: Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autopsy
Description: Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.
Study: NCT01420744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% Human Albumin infusion
Description: 1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.~Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.~Treatment will be administered over a 5-day period.~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)
Study: NCT01823900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation
Description: Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
Study: NCT03295565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Cabazitaxel 25mg/m2 IV, once every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide 160mg oral taken daily
Study: NCT03073551

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wii Group
Description: Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
Study: NCT01823900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference formulation
Description: Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
Study: NCT03033888

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health-Literacy Focused Education Session
Study: NCT04181788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.
Study: NCT00212017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voglibose

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet and exercise therapy
Study: NCT03189381

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cohort A
Description: Cohort A - WBRT dose = 25 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cohort B
Description: Cohort B - WBRT dose = 20 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0 Gy
Study: NCT01711060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balloon catheter
Study: NCT00251004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: oral, bis in diem/twice a day (bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: oral, bis in diem/twice a day (bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid (MPA)
Description: 2 oral capsules of mycophenolic acid 360mg administered bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A (CsA)
Description: CsA dose adjustments were based on CsA trough levels (C0).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Description: CsA dose adjustments were based on CsA trough levels (C0).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Description: CsA dose adjustments were based on CsA trough levels (C0).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
Study: NCT04232709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared electronic patient record
Description: MedChart allows access to a shared electronic patient record that contains selected information related to a patient's cancer treatment. If a patient contacts the after-hours telemedicine service, the oncology nurse will have access to this shared record
Study: NCT00887744

Intervention type: DEVICE
Group type: OTHER
Intervention: Aperius® Percutaneous Interspinous Spacer
Description: Implantation of the Aperius® device
Study: NCT03936452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy
Study: NCT02508298

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG
Description: HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG
Description: HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG
Description: HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green Retention test
Description: As decribed in arm descriptions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liver stiffness measurement
Description: As decribed in arm descriptions; perfromed by ARFI
Study: NCT02508298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spleen stiffness measurement
Description: As decribed in arm descriptions; performed by ARFI
Study: NCT00830076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo sitagliptin
Description: Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo sitagliptin
Description: Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo metformin
Description: Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo metformin
Description: Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
Study: NCT03286127

Intervention type: OTHER
Intervention: specialized palliative care
Description: specialized palliative care provided in different settings

Intervention type: OTHER
Intervention: specialized palliative care
Description: specialized palliative care provided in different settings

Intervention type: OTHER
Intervention: specialized palliative care
Description: specialized palliative care provided in different settings
Study: NCT04692727

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: * Hamstring, quadriceps, gastrocnemius, iliopsoas, iliotibial band (ITB), lateral and medial retinaculum stretching exercises~* Isometric exercises of vastus medialis, gluteus medius and external rotators~* Isotonic exercises of vastus medialis, gluteus medius and external rotators~* Closed kinetic chain exercises~* Balance and coordination exercises~* Core stabilization exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: * Hamstring, quadriceps, gastrocnemius, iliopsoas, iliotibial band (ITB), lateral and medial retinaculum stretching exercises~* Isometric exercises of vastus medialis, gluteus medius and external rotators~* Isotonic exercises of vastus medialis, gluteus medius and external rotators~* Closed kinetic chain exercises~* Balance and coordination exercises~* Core stabilization exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: * Hamstring, quadriceps, gastrocnemius, iliopsoas, iliotibial band (ITB), lateral and medial retinaculum stretching exercises~* Isometric exercises of vastus medialis, gluteus medius and external rotators~* Isotonic exercises of vastus medialis, gluteus medius and external rotators~* Closed kinetic chain exercises~* Balance and coordination exercises~* Core stabilization exercises
Study: NCT01475955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broad Area ALA 2 hour incubation
Description: 20% ALA broad area 2-hour incubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: broad area ALA 3-hour incubation
Description: 20% ALA broad area 3 hour incubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spot ALA 2 hour incubation
Description: 20% ALA spot 2 hour incubation
Study: NCT02688374

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment B: Nicotinell 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicotinell

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment B: Nicotinell 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicotinell

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment B: Nicotinell 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicotinell